OssDsign surpasses 200 patients in its prospective spinal fusion registry PROPEL
Uppsala, August 16, 2023. OssDsign AB (publ.) today announces that the company has enrolled 200 patients in the multi-center, prospective spinal fusion registry, PROPEL. The registry was initiated in March 2022, to gather real-world data from patients who have been treated with OssDsign Catalyst."This important milestone reflects our ability to collect clinically relevant data and is a direct result of the high level of interest from surgeons to continue using OssDsign Catalyst, resulting in a growing number of patients being included in PROPEL. The collection of robust clinical evidence is